16:25:56 Europe / Stockholm

Prenumeration

2023-11-10 15:09:00

Redeye updates its estimates following Surgical Science’s Q3 2023 report, which featured considerably lower-than-expected sales. EBITDA and EBIT margins exceeded our estimates by c3%-points. We judge growth will recover in 2024e and nudge down our valuation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/